A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects
NCT ID: NCT07043634
Last Updated: 2025-06-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
24 participants
INTERVENTIONAL
2025-06-15
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The total expected study duration is at least 11 days from the day of check-in for Period 1 to the end of Period 2.
There will be a washout period of at least 07 days will be maintained in between the periods.
Treatment will be as follows:
(A): Fixed dose combination (FDC) of 24 mg ER Torsemide + 30 mg Spironolactone tablet without food.
Dose: 1x (24 mg +30 mg) FDC tablet
Treatment (B):
FDC (24 mg ER Torsemide + 30 mg Spironolactone) tablet with food. Dose: 1x (24 mg +30 mg) FDC tablet
Route of Administration for both treatments: Oral
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
FDC (24 mg ER torsemide and 30 mg Spironolactone) tablet without food
FDC (24 mg ER torsemide and 30 mg Spironolactone) tablet without food
FDC (24 mg ER torsemide and 30 mg Spironolactone) without food
FDC without food
FDC (24 mg ER torsemide and 30 mg Spironolactone) with food
FDC with food
FDC (24 mg ER torsemide and 30 mg Spironolactone) tablet with food
FDC (24 mg ER torsemide and 30 mg Spironolactone) tablet with food
FDC (24 mg ER torsemide and 30 mg Spironolactone) without food
FDC without food
FDC (24 mg ER torsemide and 30 mg Spironolactone) with food
FDC with food
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FDC (24 mg ER torsemide and 30 mg Spironolactone) without food
FDC without food
FDC (24 mg ER torsemide and 30 mg Spironolactone) with food
FDC with food
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Healthy human adult subjects within the age range of 18 to 45 years \[both inclusive\].
2. Weight not less than 50 kg for male and 45 kg for female and BMI 18.50 to 29.99 kg/m2 \[both inclusive\].
3. Willingness to provide written informed consent to participate in the study.
4. Subjects should be non-smoker \[defined as someone who has stopped smoking for a year before the date of screening\] and should not be consuming tobacco containing products.
5. Free of significant diseases or clinically significant abnormal findings during screening, medical history, physical examination, laboratory evaluations, 12-lead ECG, Chest X-ray \[PA view\].
6. Absence of disease markers of HIV 1 and 2, Hepatitis B and C and Syphilis.
7. Subject should be literate.
8. Male subjects must be using two acceptable methods of contraception (e.g., spermicidal gel plus condom) for the entire duration of the study, and upto the study completion visit. Subjects must refrain from fathering a child in the next two weeks following the last study drug administration or have undergone vasectomy (vasectomy must have been done more than 6 months prior to first dosing). Contraceptive usage requirement will be conveyed during the inform consent process. Subjects will be advised to follow effective method of contraception until 2 weeks after the last dose is given.
9. Female subjects of childbearing potential must be using two acceptable methods of contraception, (e.g., intra-uterine device (IUD) plus condom, spermicidal gel plus condom, diaphragm plus condom, etc.), from the time of screening and for the duration of the study and for two weeks following the last study drug administration. Contraceptive usage requirement will be conveyed during the inform consent process (or) Postmenopausal women for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy have been performed).
Exclusion Criteria
1. History or presence of significant: cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, musculoskeletal, psychiatric disease/disorder.
2. History or presence of significance:
Asthma, urticaria, or other allergic-type reactions after taking Torsemide, Spironolactone or any other drug.
Ulceration or history of gastric and/or duodenal ulcer. Stomach or intestinal bleeding. Jaundice in the past 6 months. Internal bleeding.
3. Hypersensitivity or allergy to Torsemide, Spironolactone or any of the excipients.
4. History of alcohol or drug abuse in the past one year.
5. Family history of bleeding disorders.
6. History of difficulty in passing urine or emptying the bladder or of incontinence.
7. Have donated 500 mL or more blood within 90 days before receiving the first dose of the study drug.
8. Subjects who have participated in another clinical study in the past 3 months prior to commencement of this study.
9. Any difficulty in the accessibility of forearm veins for cannulation or blood sampling and or difficulty with donating blood.
10. Refuse to abstain from food for at least 10 h prior to dosing and for at least 4 h after dosing in each period.
11. Refuse to abstain from food for at least 10 h prior to start of consumption of high-fat high-calorie breakfast and at least 4 h post dose.
12. Subject who refuses to consume the 100% high fat high calorie breakfast prior to dosing\*.
13. Refuse to abstain from fluid for at least 1 h before and 1 h after dosing in each period (except 240 ± 2 mL water given for dosing).
14. Found positive during breath alcohol test done during period one check-in and inability to abstain from alcohol till the end of the study.
15. Found positive during urine drug screening done prior to period one check-in.
16. Found positive screening results for Hepatitis B, Hepatitis C, HIV, or Syphilis.
17. History of difficulty in swallowing tablets.
18. Received any medication \[including over-the-counter products\], herbal products for 14 days preceding the study.
19. Use of enzyme-modifying drugs within 30 days prior to receiving the first dose of study medication.
20. History of dehydration from diarrhea, vomiting, or any other reason within 24 hours prior to check-in of period one.
21. Consumption of xanthine-containing food and beverages (chocolates, tea, coffee, or cola drinks) for at least 48 hours prior to check-in of period one.
22. Consumption of grapefruit or its products within the 48 hours prior to check-in of period one.
23. Female subjects are found to be positive during pregnancy tests done prior to period one check-in.
24. Lactating females.
25. Investigator/Physician feels that it is not in the subject's and/or study's best interest to enroll the subject.
\-
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sarfez Pharmaceuticals, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Salim Shah, PhD, JD
Role: STUDY_CHAIR
Sarfez Pharmaceuticals, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sarfez Pharmaceuticals
Vienna, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Salim Shah, PhD, JD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SAR-HS-004-24
Identifier Type: -
Identifier Source: org_study_id